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Abstract
Objective
We did a systematic review of studies comparing discontinuation of tumor necrosis factor
alpha (TNF) antagonists in rheumatoid arthritis (RA) patients, pooled hazard ratios and
assessed clinical and methodological heterogeneity.
Methods
We searched MEDLINE and EMBASE until June 2015 for pairwise hazard ratios for discon-
tinuing infliximab, etanercept, and adalimumab from cohorts of RA patients. Hazard ratios
were pooled using inverse variance weighting and random effects estimates of the com-
bined hazard ratio were obtained. Clinical and methodological heterogeneity was assessed
using the between-subgroup I-square statistics and meta-regression.
Results
Twenty-four unique studies were eligible and large heterogeneity (I-square statistics > 50%)
was observed in all comparisons. Type of data, location, and order of treatment (first or sec-
ond line) modified the magnitude and direction of discontinuation comparing infliximab with
either adalimumab or etanercept; however, some heterogeneity remained. No effect modi-
fier was identified when adalimumab and etanercept were compared.
Conclusion
Heterogeneity in studies comparing discontinuation of TNF antagonists in RA is partially
explained by type of data, location, and order of treatment. Pooling hazard ratios for
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discontinuing TNF antagonists is inappropriate because largely unexplained heterogeneity
was demonstrated when random effect estimates were calculated.
Introduction
The tumor necrosis factor alpha (TNF) antagonists target a cytokine that regulates inflamma-
tion in multiple diseases, including rheumatoid arthritis (RA) [1]. Evidence on the relative effi-
cacy and safety of these medications is indirect and incomplete because no randomized
controlled trials (RCTs) directly compare two or more TNF antagonists in RA patients [2].
Lack of efficacy and adverse effects are the most common reasons for discontinuing TNF
antagonists [3–9], and therefore discontinuation risk is a good measure of the benefit-harm
balance of these medications [10]. Hence, comparison of discontinuation risk of different TNF
antagonists can help in treatment decisions, especially selection of an individual medication.
Since their introduction in the late 1990s, multiple observational studies have compared
discontinuation of TNF antagonists, but the results were inconsistent [11–15] due to methodo-
logical and clinical heterogeneity. Methodological heterogeneity, defined as “variability in
study design and risk of bias” [16], may be caused, for example, by differences in data collec-
tion. Clinical heterogeneity, defined as “variability in the participants, interventions and out-
comes” [16], could be caused by differences in location and dates, or frequency of dose
adjustments. A previous systematic review summarized hazard ratios for discontinuing TNF
antagonists but failed to identify predictors of methodological or clinical heterogeneity [15].
The objective of this study is to investigate methodological and clinical heterogeneity in hazard
ratios for discontinuing TNF antagonists in RA patients.
Methods
Systematic literature search
Electronic databases (MEDLINE and EMBASE) to June 2015 were searched using the follow-
ing strategy: (1) adalimumab.mp. (2) infliximab.mp (3) etanercept.mp. (4) tumour necrosis
factor antagonists.mp. or Receptors, Tumour Necrosis Factor/ (5) 1 or 2 or 3 or 4 (6) (patient
compliance or adherence or persistence or discontinuation or switching or treatment dura-
tion).mp. [mp = ti, ab, sh, hw, tn, ot, dm, mf, ps, rs, nm, ui] (7) rheumatoid arthritis.mp. or
rheumatoid arthritis/ (8) 5 and 6 and 7. Additional studies were identified by reviewing refer-
ence lists of publications meeting the inclusion criteria and other published reviews.
Selection criteria for studies
We included studies of RA patients treated with infliximab, adalimumab, or etanercept that
met the following criteria:
Study design. Cohort studies with multiple TNF antagonists. RCTs were excluded due to
differences between RA patients in RCTs and those treated in routine clinical practice [17–20].
Studies were selected regardless of the language and the type of publication (full articles,
abstracts, or conference proceedings).
Participants. RA patients, based on either the American College of Rheumatology diag-
nosis criteria [21,22] or the clinical judgment of the care-providing physicians. Studies of mul-
tiple diseases were included only if the outcomes of interest were presented separately for RA.
TNF Antagonists Discontinuation in Rheumatoid Arthritis- Meta Analysis
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Types of interventions. First or second line treatments with infliximab, adalimumab, or
etanercept selected by the care-providing physician and/or the patient. Studies of the newer
TNF antagonists, such as certolizumab pegol or golimumab, were excluded due to shorter
availability and fewer studies [15].
Duration of follow-up. At least one year from treatment initiation.
Outcome of interest. Pairwise hazard ratios for discontinuation: infliximab vs. etaner-
cept, infliximab vs. adalimumab, and adalimumab vs. etanercept.
Data extraction
Two reviewers (AF and GG/DS) independently selected studies and extracted data. In case of
a discrepancy, a decision was reached by consensus. Authors of published studies were con-
tacted when reports were incomplete, confusing, or difficult to interpret. The reviewers
extracted as-reported hazard ratios, and 95% confidence intervals (CI) or p-value. If the hazard
ratio for a specific comparison was missing, we attempted to calculate it using indirect com-
parison methodology [23] or synthesis of estimates from subgroups. To prevent the use of
duplicate or overlapping data from the same source, we selected a single hazard ratio from a
fully-published manuscript with the largest population for each comparison and data source.
Risk of bias
We identify two specific sources of bias in studies of discontinuation and included only studies
with low risk of bias, defined as:
1. The study outcome was discontinuing the individual medication or switching to a second
biologic anti-rheumatic medication. Patients remaining on treatment at the end of the
study period were censored.
2. Discontinuation was not associated with the likelihood to be included in the study; i.e., new-
user design without mandatory minimum treatment duration. In prevalent-user design,
patients who started treatment before the study period are included only if they are still
treated at the beginning of the study; hence, patients with longer use are overrepresented.
Statistical analysis
Hazard ratios for discontinuation with 95% CI were combined using an inverse variance
approach, and data were recorded on the natural logarithm scale [24]. We calculated random
effect estimates [25] because substantial heterogeneity has previously been observed [11,15].
In the absence of a definitive statistical test to assess whether a factor causes heterogeneity,
we identified effect modifiers. We tested for the association between the effect size and clinical
factors: continent, order of treatment, age, sex, and Disease Activity Score (DAS-28) as well as
methodological factors: type of data and duration of follow-up. Categorical factors consisted of
continent (Europe, Asia, or America), order of treatment (first or second line), and type of
data (clinical charts, disease or drug registries, or administrative claim data). For these factors,
we conducted between-subgroup I-square statistics, and estimated the significance using chi-
squared test [26]. For continuous factors, i.e., age, sex, baseline DAS-28, and duration of fol-
low-up, we conducted meta-regression [27] with a fixed effect model and weights based on the
inverse of the variance of the logarithm of the hazard ratio. For factors that were reported as
the average or the median of populations, we stratified the regression model by type of central
measure. A significant association between a factor and the effect size was defined as a two-
tailed p-value <0.05 for both categorical and continuous variables. Analyses were conducted
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using the Review Manager (RevMan) statistical software (Version 5.3, The Nordic Cochrane
Centre, The Cochrane Collaboration, Denmark) and SAS software package (Version 9.4, SAS
Institute Inc., Cary, NC).
Results
A total of 2,409 unique citations were identified and screened (Fig 1), and 24 unique studies
were eligible for inclusion (Table 1). Forty studies reported hazard ratios for discontinuing
TNF antagonists but were excluded, most commonly because the study drugs were not com-
pared (S1 Table in the on-line supporting information). Two of the studies were excluded due
to high risk of bias [28,29]. Three studies reported outcomes from the SSTAG/ARTIS Swedish
registry [5,30,31], two studies from the Spanish BIOBADASER 2.0 registry or hospitals con-
tributing to it [6,32], two studies from the Italian Monitornet registry [33,34], two studies from
the American claim database MarketScan [35,36], and three studies from the national insur-
ance claim data or hospitals in South Korea [37,38] (Table 1).
Fifteen studies (20,796 patients) from unique data sources compared infliximab and adali-
mumab with the overall pooled hazard ratio of 1.08 (95% C] 0.92–1.27) (S1 Fig). Fifteen stud-
ies (23,671 patients) from unique data sources compared infliximab and etanercept with the
overall pooled hazard ratio of 1.22 (1.00–1.49) (S2 Fig). Seventeen studies (27,799 patients)
from different data sources showed higher risk of discontinuing adalimumab compared with
etanercept and the overall pooled hazard ratio was 1.17 (1.08–1.27) (S3 Fig). There was signifi-
cant heterogeneity between studies for all three comparisons, with I square statistics of 86%,
92%, and 56%, respectively.
Assessment of methodological and clinical heterogeneity is presented in Table 2. In analysis
of categorical factors, effect modifications of the type of data (Fig 2), location (Fig 3), and
order of treatment (Fig 4) was observed in comparisons of infliximab with adalimumab or
etanercept, but not comparing adalimumab with etanercept. This effect modification was
expressed as I squared statistics of 69.1–92.7%, with p-value <0.05 in Chi squared test. These
percentages could be interested as following: 69.1–92.7% of variation across subgroups in each
comparison is due to heterogeneity rather than chance. We also noticed that in all compari-
sons, not all subgroup hazard ratios reach statistical significance level and in most cases a resid-
ual within subgroup heterogeneity was observed. For example, in analysis of type of data (Fig
2), when comparing infliximab with etanercept, we observed significant heterogeneity between
the three subgroups compared: studies based on clinical charts, those conducted on registries
and analyses of claim data (I square statistics of 69.1%). Only studies conducted on registries
had a significant pooled hazard ratio of 1.49 (95% CI 1.23–1.81), but they also consisted the
largest subgroup. A reversed direction of hazard ratio was estimated in two studies based on
clinical charts and three analyses of claim data, i.e., lower risk of discontinuing infliximab,
but these polled estimates did not reach significance level. We noticed residual heterogeneity
within each subgroup: clinical chart, registries, and claim data.
In analysis of continuous factors (Table 2), the proportion of female patients using inflixi-
mab modified the hazard ratio in comparison of infliximab with etanercept. However, in the
presence of multiple comparisons and in the absence of similar effect of the proportion of
female patients using etanercept we discarded this finding. Finally, duration of follow up, age,
and baseline DAS-28 did not modify the hazard ratios (Table 2).
Discussion
This review explored sources of clinical and methodological heterogeneity in studies compar-
ing discontinuation of TNF antagonists in RA patients. The type of data (i.e. charts, registries,
TNF Antagonists Discontinuation in Rheumatoid Arthritis- Meta Analysis
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Fig 1. QUOROM flow chart. 1 SSATG is part of ARTIS, data were overlapping with Neovius 2015. 2 Carlos Haya
hospital is included in BIOBADASER 2.0, data were overlapping with Gomez-Reino 2012. 3 Data from South Korea
NIH, also known as Health Insurance Review and Assessment Service, were included in Lee 2014. 4 Data from
MonitorNet were included in Scire 2013. 5 Data from MarketScan were included in Johnstone 2015.
doi:10.1371/journal.pone.0168005.g001
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Table 1. Characteristics of eligible studies.
Reference Data source Period RA diagnosis Type of users Previous
DMARDs
Persistence/
discontinuation
N (INF, ADA,
ETA)
Follow up
Kristensen
2006 [39]
South Swedish
Arthritis Treatment
Group (SSATG),
Sweden
March 1999
—December
2004
Clinical judgement by
the treating
physician. 98%
fulfilled the ACR
1987 criteria
Biologics
naive
2, including
MTX previously
without
satisfactory
response
Registered prospectively,
based on the judgement
of the treating physician.
1161 (721,
440)
Not reported
Fernandez-
Nebro 2007
[32]
A tertiary care
center, a structured
clinical follow-up
protocol, Spain
March 1999
—January
2006
ACR criteria Anti-TNF-
naive
2, including
MTX previously
without
satisfactory
response
"Definitive" 161 (60, 22a,
79)
Mean (STD) 20.6
(16.8) months;
range 0.0–62.2;
median 24
Borah 2009
[40]
Claims data (I3
Innovus), a large
managed health
care plan, US
January
2005—
December
2006
1 medical claim
with RA as the
primary diagnosis
prior to the index
date
6 months
without
dispensing
Not reported >30-day medication-free
gap or switching
1230 (0,
527, 703)
12 months
Du Pan 2009
[41]
Swiss Clinical
Quality
Management for
Rheumatoid
Arthritis
(SCQM-RA)
registry,
Switzerland
January
1997—
December
2006
Not reported 78% anti-TNF
naive
Not reported > 6 month medication-
free gap
2364 (595,
882, 887)
Not reported
Marchesoni
2009 [42]
LORHEN registry,
Italy
January
1999 –
December
2001
ACR criteria First course in
the registry
1 course of
combination
therapy, one of
which should
always be MTX
without
satisfactory
response
Discontinuation due to
clinical remission—
censored
1064 (519,
303, 242)
6–36 months of
follow-up, or
discontinued
therapy within 6
months
Hetland
2010 [43]
DANBIO registry,
Denmark
October
2000–3 April
2009
clinical judgement by
the treating physician
Not reported 1 without
satisfactory
response
Not reported 2326 (1134,
675, 517)
Median (IQR) for
adalimumab, 20
months 7–39);
etanercept, 21
months (9–42);
infliximab, 16
months (5–36)
Cho 2012
[37]
National Health
Insurance (NHI)
claim database,
South Korea
January
2007—
December
2009
A diagnosis of RA
(ICD10-M05 or M06)
New-user
design
(washout
period from
January 2007
to June 2007
without anti-
TNF)
Not reported >14-week refill free gap
Persistence = the number
of days between the first
and last refills
388(26b,
219, 143)
Not reported
Gomez-
Reino 2012
[6]
BIOBADASER 2.0,
Spain
February
2000 –
December
2010
Not reported First treatment Not reported Not reported 2097 (1273,
761, 873)
First year
Greenberg
2012, [44]
CORRONA
registry, US
February
2002—
March 2008
Not reported (1) Biologics
naive (2) First
time switchers
Not reported Data was collected every
3 months. " we used the
visit dates of reported
initiation and visit dates of
reported discontinuation"
(1) 1475
(535,
460,480)
(2) 616 (166,
311, 139)
Not reported
Soderlin
2012 [31]
South Swedish
Arthritis Treatment
Group (SSATG)
biologics register,
Sweden
March 1999
—December
2005
A clinical diagnosis First anti-TNF
course
MTX alone or in
combination
without any
satisfactory
response and/or
intolerance
Not reported 534 A minimum of 3.6
years
Caporali
2013 [33] [A]
Monitornet
database, Italy
from
January
2007
Not reported First course Not reported Not reported 1992(426,
685, 881)
Not reported
(Continued)
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Table 1. (Continued)
Reference Data source Period RA diagnosis Type of users Previous
DMARDs
Persistence/
discontinuation
N (INF, ADA,
ETA)
Follow up
Chen 2013
[45] [A]
National Health
Insurance (NHI),
Taiwan
Not reported Not reported Anti-TNF
naïve
Not reported >84-day refill free gap 4592 (0,
1982,2609)
First year
Hishitani
2013 [46]
Osaka BiRD
registry, Japan
September
1999—April
2012
ACR criteria Biologics
naivec
1 Discontinuation due to
remission or
miscellaneous reasons
and missing data were
treated as censored
cases
401d (103,
58, 143)
Not reported
Johnston
2013 [35] [A]
Truven Health
MarketScan
databases, US
January
2010—June
2011
Not reported Used at least
one biologic
prior to index
Not reported A 90-day medication-free
gap or switching to
another biologic
7515e (672,
1504, 1114)
Not reported
Scire 2013
[34]
Monitornet
database, Italy
January
2007—April
2012
Not reported Anti-TNF-
naive
Failure Medication
interruption  3 months.
Persistence = the number
of days between the first
and last day of treatment
2640 (718,
887, 1035)
Not reported
Senabre-
Gallego
2013 [47,48]
[A]
"our local cohort"
Asociacio´n para la
Investigacio´n en
Reumatologı´a de la
Marina Baixa
(AIRE-MB), Spain
January
2001—
November
2011
Not reported Not reported Not reported Not reported 318 (97,
116, 105)
Not reported
Fisher 2014
[49]
BC Ministry of
Health databases,
Canada
March 2001
—December
2009
2 outpatient at least
60 days apart or 1
inpatient diagnosis of
RA (ICD-9 714.XX)
the three years prior
to TNF-b initiation
Biologics
naive
Not reported 180 days medication-
free gap or switching to
another ‘biologic’
2286 (620,
344, 1322)
Not reported
Flouri 2014
[50]
Hellenic Registry of
Biologic Therapies,
Greece
January
2004—April
2011
according to the
treating physician
79% anti-TNF
naïve
1 "registered prospectively" 1028
patients,
1297
courses
(560, 435,
302)
The median (IQR)
3.0(1.2–6.2) years
for infliximab, 2.9
(1.1–5.9) years for
adalimumab, and
2.9(1.1–5.0) years
for etanercept.
Frazier-
Mironer 2014
[51,52]
Medical charts,
eight rheumatology
centers, France
March 2005
—April 2011
1987 ACR criteria (1) Biologics
naïve (2)
second anti-
TNF
medication
Not reported The first definitive
treatment interruption or
last observation on
treatment after initiation
(exact time collected via
the patient chart):
indicated by the treating
rheumatologist, or no
consecutive re-
introduction of treatment
(1) 706 (99,
203, 404) (2)
231 (20f,
105, 106)
2–6 years
Kang 2014
[53,54]
Medical charts,
Chonnam National
University Hospital,
Gwangju, South
Korea
December
2002—
November
2011
ACR criteria Anti-TNF
naive
Not reported Not reported 144 (22, 48,
39)
At least one year
Lee 2014
[38] [A]
Health Insurance
Review and
Assessment
Service, South
Korea
2006—
December
2010
2 prescriptions of
DMARD under the
diagnosis of RA
New-user
design
(washout
period without
DMARDs
during 2006)
Not reported Medication-free gap
of > half of the days
supply of the previous
prescription, or switching
to other TNF inhibitors
2203 (458,
1202, 543)
Not reported
Neovius
2015, [5]
Swedish Biologics
Register (ARTIS),
Sweden
January
2003—
December
2011
Assessment of the
treating
rheumatologists
Anti-TNF-
naive
Not reported As reported by the
treating rheumatologist,
due to any cause, except
for pregnancy and
remission.
discontinuation
2898 Up to 5 years
(Continued)
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Table 1. (Continued)
Reference Data source Period RA diagnosis Type of users Previous
DMARDs
Persistence/
discontinuation
N (INF, ADA,
ETA)
Follow up
Johnston
2015 [55]
Truven Health
MarketScan
database, US
January
2010 –
December
2011
ICD-9-CM codes
recorded on medical
claims between
January 2009 and
March 2012
Previously
used 1 other
biologic
Not reported 90 days Medication-free
gap or switching to
another biologic
9782g (922,
2179, 16750
Not reported
a Patients treated with adalimumab were excluded due to the reduced sample size.
b Patients treated with infliximab were excluded from analysis, since this medication was not available throughout the analysis period
c Patients who started therapy before entering the registry were included.
d Including 97 patients treated with tocilizumab.
e Including patients treated with abatacept (1297), certolizumab (681), golimumab (951), and rituximab (622).
f Patients treated with infliximab were excluded from analysis of second anti-TNF due to small numbers.
g Including patients treated with abatacept (1759), certolizumab (962), golimumab (1195), and tocilizumab (1090)
[A] Abstract, ACR American Collage of Rheumatology, DMARDs Disease Modifying Anti-Rheumatic Drugs, ICD-9 the International Classification of
Diseases Ninth Revision, ICD-9-CM the International Classification of Diseases Ninth Revision Clinical Modification, ICD10 the International Classification
of Diseases Tenth Revision, IQR Interquartile Range, MTX Methotrexate, STD Standard Deviation, TNF Tumor Necrosis Factor alpha, US United Stated of
America
doi:10.1371/journal.pone.0168005.t001
Table 2. Assessment of heterogeneity: association between study design and patient characteristics and effect sizes.
Factor tested and statistics Infliximab vs.
adalimumab
Infliximab vs.
etanercept
Adalimumab vs.
etanercept
Clinical heterogeneity Continent I2, p-value 82.7, <0.0001 91.3, <0.0001 0, 039
Order of treatment I2, p-value 77.5, 0.03 92.1, 0.004 0, 0.49
Age (infliximab users), regression parameter (standard
error), p-value
0.015 (0.032), 0.66 0.006 (0.029), 0.8
Age (adalimumab users), regression parameter
(standard error), p-value
0.037 (0.034), 0.30 n/a 0.008 (0.022), 0.72
Age (etanercept users), regression parameter
(standard error), p-value
n/a 0.142 (0.085), 0.14 -0.006 (0.022), 0.78
Sex (infliximab users), regression parameter (standard
error), p-value
0.77 (0.532), 0.18 4.668 (1.49), 0.01 n/a
Sex (adalimumab users), regression parameter
(standard error), p-value
0.757 (0.443), 0.12 n/a -0.140 (0.398), 0.73
Sex (etanercept users), regression parameter
(standard error), p-value
n/a 2.054 (0.929), 0.05 -0.186 (0.486), 0.71
Baseline DAS (infliximab users), regression parameter
(standard error), p-value
0.055 (0.084), 0.54 -0.234 (0.338), 0.51 n/a
Baseline DAS (adalimumab users), regression
parameter (standard error), p-value
0.051 (0.072), 0.51 n/a -0.088 (0.165), 0.61
Baseline DAS (etanercept users), regression
parameter (standard error), p-value
n/a -0.225 (0.266), 0.43 -0.145 (0.193), 0.48
Methodological
heterogeneity
Type of data I2, p-value 79.4, 0.008 69.1, 0.04 11.6, 0.32
Duration of follow-up, regression parameter per 10
years (standard error), p-value
-0.004 (0.001), 0.62 -0.033 (0.03), 0.30 -0.001 (0.004), 0.90
P-value <0.05 represents a significant effect of the factor tested on the hazard ratio in the individual comparison (between-subgroup I-square statistics [26]
and p-value of chi-squared test for categorical factors, and meta-regression [27] with a fixed effect model and weights based on the inverse of the variance
of the logarithm of the hazard ratio for continuous factors).
DAS- disease activity score; n/a–not applicable
doi:10.1371/journal.pone.0168005.t002
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or claims) modified the effect size in comparisons of infliximab with etanercept or adalimu-
mab. However, this factor was not responsible for all the heterogeneity. Different types of data
are susceptible to different types of biases. Registries are susceptible to selection bias caused by
the volunteer enrollment and data collection [56]. Administrative data are susceptible to con-
founding due to the absence of clinical variables and exposure ascertainment bias because of
the uncertainty whether patients who refilled the medication actually used it. Type of data also
determines how the outcome, discontinuation, is defined. In analysis of registries or medical
charts, discontinuation is recorded by physicians, either during a routine visit or in real-time.
In analysis of administrative data, discontinuation is usually ascertained using prescription-
refill analysis and applying grace periods [57]. Comparisons of discontinuing TNF antagonists
are especially sensitive to these differences in outcome definition because of the intermittent
dosing schedules and different lengths of dose interval for different medications. Comparisons
of infliximab were more sensitive to the data source probably because it has a significantly lon-
ger dose interval than adalimumab and etanercept.
A second hazard modifier is location. In European countries, the risk of discontinuing eta-
nercept and adalimumab is lower compared to infliximab, but in America, patients on inflixi-
mab had lower discontinuation risk compared to adalimumab and similar risk as patients
treated with etanercept. In a previous review reported similar proportions of patients from
European and non-European countries who discontinued any TNF antagonists [15], but the
results were not presented separately for each individual medication. Souto et al [15] failed to
determine whether these findings are constant across different medications.
Fig 2. Assessment of methodological heterogeneity: subgroup analysis for type of data.
doi:10.1371/journal.pone.0168005.g002
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Hazard ratio estimates were also modified by the order of treatment (first or second line) in
comparisons of infliximab with adalimumab or etanercept. However, in these comparisons the
only two studies that reported hazard ratios for second line treatment were American studies
Therefore, we cannot rule out that the modification observed is related to location and not to
order of treatment.
Age, sex, baseline disease activity score (DAS), and duration of follow-up did not modify
the hazard ratios. The absence of modification by baseline DAS opposes the hypothesis by
Greenberg 2014 [58] that the difference in estimates between American and European studies
is caused by differences in disease severity.
The results of this review question the reliability of hazard ratios for discontinuing TNF
antagonists. Specifically, the residual heterogeneity within subgroups may indicate that stable
results cannot be duplicated by different researchers nor can conclusive scientific findings be
obtained. Alternately, researchers may not be measuring the same outcome because different
types of data, and possibly different definitions of discontinuation, modified the hazard ratios.
Standardization of methodological approaches may help achieving the requisite reliability.
There are several limitations to our study. First, we were unable to adequately assess risk of
bias in the absence of a specific evaluation tool for discontinuation studies. Available tools for
observational studies, such as Newcastle-Ottawa scale [59], do not assess relevant items such as
new-user design and ascertainment of discontinuation. The other tools, e.g., STROBE state-
ment [60], assess the quality of reporting and not the risk of bias. Second, in the absence of a
statistical test to determine causes of heterogeneity between studies, we could only assess effect
Fig 3. Assessment of clinical heterogeneity: subgroup analysis for location.
doi:10.1371/journal.pone.0168005.g003
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modification. Last, we found significant residual heterogeneity within many of the subgroups
and therefore pooled estimates were impossible to interpret.
This review had several strengths including the wide scope: no temporal or linguistic con-
straints. Second, to minimize bias, this review included only studies reporting adjusted
hazard ratios for discontinuation. Earlier systematic reviews summarized proportions of
discontinuation for each TNF antagonist individually [14,15]. Because these proportions
were crude estimates from observational data, comparisons between medications were most
likely confounded. Last, we identified two major risks of bias in discontinuation studies and
applied them in study selection.
Conclusions
Substantial heterogeneity was found in studies estimating head-to-head hazard ratios for dis-
continuing TNF antagonists in RA patients due to differences in type of data, location, and
order of treatment. The heterogeneity observed shows that stable results have not been dupli-
cated by different researchers and conclusive scientific findings cannot be obtained by pooling
results.
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